BioWorld Asia

Jan. 30, 2002

UroGene, Pierre Fabre Enter 3-Year Cancer Collaboration

PARIS UroGene SA entered into a three-year research collaboration with Pierre Fabre M dicament to discover and develop new active compounds to treat prostate cancer against a validated biological target identified by UroGene. (BioWorld International) Read More

Symphogen Raises US$15M To Develop Polyclonal Antibodies

Peptide Study Yields Insights Into Autoimmune Disease Mechanisms

Synt:em, Baxter Collaborate On Peptide Mimetics Of MAbs

UK Creating Centers To Help Capitalize On Genetics Progress

Galapagos, Exelixis Collaborate To Analyze Functions Of Genes

Biogen Paying Schering $20M Or More Over MS Drug Patents

BIA Calls For More Support To Deal With Animal Rights Activists

Dutch Biotech Association Seeks Clearer Signals From Politicians

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 10, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...